![\"\"](\"https:\/\/dailybusinessgroup.co.uk\/wp-content\/uploads\/2026\/05\/James-McIlroy-of-EnteroBiotix.png\")
Drugs developer EnteroBiotix has raised \u00a319 million in one of the largest investments into a Scottish biotech company in recent years.<\/p>\n
It will support one of the world\u2019s most extensive clinical trials of treatments for irritable bowel syndrome (IBS).\u00a0<\/p>\n
IBS affects up to 1 in 10 of the global population, with up to twice as many women diagnosed compared to men.<\/p>\n
The trial involving around 300 patients is now under way, with the drug manufactured by EnteroBiotix in Scotland. Results from the trial are due in the second half of 2027.\u00a0\u00a0<\/p>\n
The funding round was led by life science investor Thairm Bio and the Scottish National Investment Bank, with participation from existing investors.<\/p>\n
EnteroBiotix has raised in excess of \u00a365m since the company was founded by CEO Dr James McIlroy in 2017. He launched the company while training to be a doctor.<\/p>\n
\u201cWe aim to address underlying disease biology and deliver clinically meaningful improvements in patient outcomes,\u201d he said.<\/p>\n
\u201cOur mission is to redefine the standard of care in gastrointestinal disease, improving the lives of patients with IBS while building a leading global biopharmaceutical company from our base in Scotland.\u201d<\/p>\n
EnteroBiotix\u2019s clinical pipeline spans IBS, liver cirrhosis, and blood cancer. The company, which is chaired by former Merck Serono CEO Elmar Schnee, has a number of strategic partnerships and research collaborations in place, including with Imperial College London.<\/p>\n
\t <\/div>\n